17 October 2023
17 October 2023
The $1.3bn deal with KBP Biosciences will be completed by the end of 2023.
Pfizer is launching a $3.5bn cost-saving programme and BioNTech expects 2023 revenues to decrease as demand for Covid treatments wanes.
Pfizer’s Elrexfio and Astellas’ Veozah are among the seven drugs recommended for approval by the European regulatory committee.
The deal will see Bristol Myers Squibb pay $58 per share in cash for a total value of $4.8bn.
Illumina has said that it will seek to challenge the European Commission’s jurisdiction over its acquisition of GRAIL in hopes of keeping the merger still on the table.
The decision on sNDA is based on data from the FLAURA2 Phase III study.
The US government's Covid-19 research programme has announced the vaccine candidates for its latest round of funding.
As AI applications in drug manufacturing widen, Leucine’s digital twin of the shop floor helps automate compliance and improve safety.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.
Give your business an edge with our leading industry insights.
